Browsing ICR Divisions by author "Bliss, Judith"
Now showing items 1-20 of 105
-
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; et al. (MASSACHUSETTS MEDICAL SOC, 2017-11-09)BACKGROUND: The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such ... -
5-fraction radiotherapy for breast cancer: FAST Forward to implementation.
Somaiah, N; Brunt, AM; Haviland, JS; Kirby, AM; Wheatley, D; et al. (Elsevier, 2023-05-19) -
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).
Banerjee, S; Tovey, H; Bowen, R; Folkerd, E; Kilburn, L; et al. (SAGE PUBLICATIONS LTD, 2020-12-01)BACKGROUND: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor ... -
Accelerated versus standard epirubicin followed by CMF versus capecitabine as adjuvant therapy of breast cancer: results of the randomised UK TACT2 trial (CRUK/05/19)
Bliss, J; banerji, J; Gillman, A; Morden, J -
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Velikova, G; Morden, JP; Haviland, JS; Emery, C; Barrett-Lee, P; et al. (ELSEVIER SCIENCE INC, 2023-11-02)BACKGROUND: Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves ... -
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron, D; Morden, JP; Canney, P; Velikova, G; Coleman, R; et al. (ELSEVIER SCIENCE INC, 2017-07-01)BACKGROUND: Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve ... -
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
Brunt, AM; Wheatley, D; Yarnold, J; Somaiah, N; Kelly, S; et al. (ELSEVIER IRELAND LTD, 2016-07-15)BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin ... -
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
Gnant, M; Dueck, AC; Frantal, S; Martin, M; Burstein, HJ; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-01-20)PURPOSE: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor-positive ... -
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz, G; Procter, M; de Azambuja, E; Zardavas, D; Benyunes, M; et al. (MASSACHUSETTS MEDICAL SOC, 2017-07-13)BACKGROUND: Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy ... -
An exploratory analysis of women’s free-text comments on their Quality of Life in the UK Standardisation of Breast Radiotherapy (START) Trials for early breast cancer
Haviland, J; Moynihan, C; Hopwood, P; Bliss, J (Elsevier, 2018-04-10) -
Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial.
Sipos, O; Tovey, H; Quist, J; Haider, S; Nowinski, S; et al. (ELSEVIER, 2021-01-01)BACKGROUND: In the TNT trial of triple negative breast cancer (NCT00532727), germline BRCA1/2 mutations were present in 28% of carboplatin responders. We assessed quantitative measures of structural chromosomal instability ... -
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
Banerjee, S; Stewart, J; Porta, N; Toms, C; Leary, A; et al. (BMJ PUBLISHING GROUP, 2021-11-01)BACKGROUND: ARID1A (AT-rich interactive domain containing protein 1A) loss-of-function mutations have been reported in gynecological cancers, including rarer subtypes such as clear cell carcinoma. Preclinical studies ... -
Biomarker-guided trials: Challenges in practice.
Antoniou, M; Kolamunnage-Dona, R; Wason, J; Bathia, R; Billingham, C; et al. (ELSEVIER INC, 2019-12-01)Biomarker-guided trials have drawn considerable attention as they promise to lead to improvements in the benefit-risk ratio of treatments and enhanced opportunities for drug development. A variety of such designs have been ... -
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast Cancer.
Dowsett, M; Kilburn, L; Rimawi, MF; Osborne, CK; Pogue-Geile, K; et al. (AMER ASSOC CANCER RESEARCH, 2022-01-01)PURPOSE: To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER+/HER2- breast cancer; and (ii) the pharmacodynamic ... -
Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?
Bhattacharya, IS; Kirby, AM; Bliss, JM; Coles, CE (ELSEVIER SCIENCE LONDON, 2018-03-01)Adjuvant radiotherapy after breast-conserving surgery has been an important component of the standard of care for early breast cancer. Improvements in breast cancer care have resulted in a substantial reduction in local ... -
Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design.
Bhattacharya, IS; Haviland, JS; Turner, L; Stobart, H; Balasopoulou, A; et al. (2021-06-14)<h4>Background</h4>For patients with early breast cancer considered at very-low risk of local relapse, risks of radiotherapy may outweigh the benefits. Decisions regarding treatment omission can lead to patient uncertainty ... -
Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design.
Bhattacharya, IS; Haviland, JS; Turner, L; Stobart, H; Balasopoulou, A; et al. (BMC, 2021-06-14)BACKGROUND: For patients with early breast cancer considered at very-low risk of local relapse, risks of radiotherapy may outweigh the benefits. Decisions regarding treatment omission can lead to patient uncertainty ... -
Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial.
Bhattacharya, IS; Haviland, JS; Hopwood, P; Coles, CE; Yarnold, JR; et al. (ELSEVIER IRELAND LTD, 2019-05)BACKGROUND: In an era of low local relapse rates after adjuvant breast radiotherapy, risks of late normal-tissue effects (NTE) need to be balanced against risk of relapse. NTE are assessed using patient-reported outcome ... -
Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository.
Kilburn, LS; Aresu, M; Banerji, J; Barrett-Lee, P; Ellis, P; et al. (BMC, 2017-11-23)BACKGROUND: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking ... -
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; et al. (NATURE PUBLISHING GROUP, 2018-04-30)Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs ...